Writer: Balqist Nadia Rahmah Editor: Oktaviani Utami Dewi

Another milestone was achieved by PT Biometrik Riset Indonesia that has been trusted by the Ministry of Health of the Republic of Indonesia in order to conduct the Facilitation of Local Change Source Active Pharmaceutical Ingredient (API) for Candesartan Bioequivalence study of six pharmaceutical industries, e.g PT Pyridam Farma Tbk., PT Bernofarm, PT Interbat, PT Hexpharm Jaya Laboratories, PT Novell Pharmaceutical Laboratories, and PT Pratapa Nirmala.

On Thursday, November 23rd 2023 Mr. Roy Himawan, S.Farm, Apt, M.K.M as Director of Pharmaceutical and Medical Devices Security, Directorate General of Pharmaceutical and Medical Devices, Ministry of Health of the Republic of Indonesia, and his team visited Biometrik for attending drug administration and blood sampling process on Candesartan bioequivalence study produced by PT Interbat.

On this special occasion, Mr. Roy Himawan said that the Local Change Source Active Pharmaceutical Ingredient project has a lot of positive impacts not only on the pharmaceutical industries, but also on general community especially all of participants involved in this study. He also hoped that Biometrik would expand its business to be a Global Contract Research Organization (CRO) in bioequivalence and clinical trial center. PT Interbat as the pharmaceutical industry on the Candesartan project also join by onsite and online study monitoring.


Biometrik has a commitment to serve the best quality and services to all valuable customers with comply to the guidelines and regulatory standards said Mrs. Effi Setiawati, Operation Director of PT Biometrik Riset Indonesia.


Leave a comment